Israeli team spurs nerve healing with implant-released gel
A team of researchers at Tel Aviv University has developed a biodegradable implant that delivers a gel capable of restoring healthy nerve function to treat diseases such as Parkinson's.
Genomic Health rolls out new prostate cancer Dx
Genomic Health launched its prostate cancer diagnostic this week with great fanfare, backed by seven studies including over 1,100 patients. The challenge ahead: convincing men that results telling them they can wait for more drastic and expensive treatment options are to be believed. There is a strong pedigree behind the technology, developed by scientists at the University of California, San Francisco and the Cleveland Clinic. Oncotype Dx measures 17 different genes to predict how aggressive a particular prostate cancer has become. Read more >>The 25 most influential people in biopharma today - 2013
Influence is a fungible asset.A lot of cash on hand can help tremendously, of course. But at this stage, who in this business hasn't seen billions incinerated in pursuit of sheer folly? Far more influential is the savvy executive who can marshal experts as well as financial resources in pursuit of a smarter, better, faster way to develop and market important new drugs.
And intelligent research strategies are far more rare than we acknowledge.
You'll find some here in our second annual report on the 25 most influential people in the industry. Read the report >>
TOP HEADLINES
Featured Story
Marina platform to deliver first-ever miRNA cancer drug for Mirna PhI
Texas biotech Mirna Therapeutics began a Phase I clinical trial of its miRNA cancer drug MRX34 with a liposomal delivery platform the company licensed from Marina Biotech. It is the first miRNA drug to advance to the clinic for cancer.
'Magic bullet' nanoparticle treats lung trauma in intensive care
A new nanoparticle drug-delivery platform created by researchers at Queen's University Belfast may be able to target and effectively treat severe lung trauma in patients in intensive care.
New polymers shatter to release drugs at specific target
A new delivery platform called chain-shattering polymers developed by researchers at the University of Illinois could hold the key to the more controlled release of drugs at localized sites and tissues.
FDA accepts Merck's sublingual allergy med license application
Merck won the FDA's acceptance of a Biologics License Application for its investigational ragweed pollen allergy tablet to be delivered under the tongue.
Scripps study reveals new RNA-drug targeting potential
In another step toward realizing the elusive potential of RNA drugs, scientists at the Scripps Research Institute have nailed down one of the mechanisms by which the gene-silencers reach their targets in the cell's nucleus.
Frederick National Lab leads nanotech boom with cancer drug delivery
Researchers at the Frederick National Laboratory for Cancer Research have developed a way to enhance delivery of a cancer drug using nanoparticles, enabling more of the toxic therapy to reach the tumor without killing healthy cells.
From Our Sister Sites
The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease.
A federal judge in Australia has put the kibosh on a half-million-dollar settlement over ill effects of Merck's ($MRK) painkiller Vioxx, a drug that has spawned billions of dollars in litigation.
POPULAR COMMENT THREADS